Streetbeat News

Price Targets

PR

B of A Securities analyst Doug Leggate has initiated coverage on Permian Resources (NYSE:PR) with a Neutral rating and set a price target of $15.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 3:39 pm

ALIT

Citigroup analyst Peter Christiansen has reinstated a Buy rating on Alight (NYSE:ALIT) and set a price target of $12 for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 3:36 pm

CAPR

Cantor Fitzgerald analyst Kristen Kluska has initiated coverage on Capricor Therapeutics (NASDAQ:CAPR) with an Overweight rating and set a price target of $8.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 3:32 pm

GOEV

Wedbush analyst Daniel Ives has initiated coverage on Canoo (NASDAQ:GOEV) with an Outperform rating and set a price target of $4 for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 3:26 pm

NVST

UBS analyst Kevin Caliendo has initiated coverage on Envista Holdings (NYSE:NVST) with a Neutral rating and set a price target of $26.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 3:23 pm

CNS

UBS analyst Adam Beatty has initiated coverage on Cohen & Steers (NYSE:CNS) with a Sell rating and set a price target of $68. This new coverage could influence investor sentiment and potentially impact CNS's stock price in the short term.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 3:19 pm

JHG

UBS analyst Adam Beatty has initiated coverage on Janus Henderson Group (NYSE:JHG) with a Sell rating and set a price target of $25.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 3:16 pm

FHI

UBS analyst Adam Beatty has initiated coverage on Federated Hermes (NYSE:FHI) with a Neutral rating and set a price target of $35.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 3:11 pm

ROIV

Piper Sandler analyst Allison Bratzel has initiated coverage on Roivant Sciences (NASDAQ:ROIV) with an Overweight rating and set a price target of $20.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 3:08 pm

HIMS

Tigress Financial analyst Ivan Feinseth has reiterated a Buy rating on Hims & Hers Health (NYSE:HIMS) and increased the price target from $14 to $15.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 3:03 pm